High-mobility group-I/Y proteins: Potential role in the pathophysiology of critical illnesses

Critical Care Medicine

Volumn 30, Issue 1 SUPPL. B, 2002, Pages

  Carvajal, Irvith M ^a   Baron, Rebecca M ^a   Perrella, Mark A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Enhanceosome; High mobility group proteins; Inflammation; Nuclear protein DNA complex; Sepsis; Transcriptional regulation

Indexed keywords

CYCLOOXYGENASE 2; DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP I PROTEIN; HIGH MOBILITY GROUP PROTEIN; HIGH MOBILITY GROUP Y PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2; INTERLEUKIN 4; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DNA CONFORMATION; GENE CONTROL; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; SEPSIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 0036162253     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200201001-00005     Document Type: Conference Paper

References (85)

1. Transcriptional activation: A complex puzzle with few easy pieces
2. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome
3. Architectural transcription factors
4. Upwardly mobile proteins. Workshop: The role of HMG proteins in chromatin structure, gene expression and neoplasia
5. HMGI/Y proteins: Flexible regulators of transcription and chromatin structure
6. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y)
7. High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function
8. The A·T-DNA-binding domain of mammalian high mobility group I chromosomal proteins: A novel peptide motif for recognizing DNA structure
9. Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y)
10. Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements
11. Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells
12. High mobility group-I(Y) protein facilitates nuclear factor-kappaB binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer
13. Enhancement of serum-responsive factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y)
14. HMG-I(Y) interferes with the DNA binding of NP-AT factors and the induction of the interleukin 4 promoter in T cells
15. Phosphorylation of the DNA-binding domain of non-histone high-mobility group I protein by cdc2 kinase: Reduction of binding affinity
16. Replacement of conserved threonines by alanine residues in high mobility group protein HMG-I(Y): Effect on DNA binding affinity
17. Acetylation of HMG-I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome
18. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene
19. Identification of the rel family members required for virus induction of the human beta interferon gene
20. The mechanism of transcriptional synergy of an in vitro assembled interferon-β enhanceosome
21. Mechanism by which the IFN-β enhanceosome activates transcription
22. Induction of high mobility group-I(Y) protein by endotoxin and interleukin-β in vascular smooth muscle cells: Role in activation of inducible nitric oxide synthase
23. Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric oxide synthase 2 by transforming growth factor-β1
24. Macrophage nitric oxide synthase gene: Two upstream regions mediate induction by interferon γ and lipopolysaccharide
25. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon γ and bacterial lipopolysaccharide
26. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase
27. An interferon-γ-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-γ and lipopolysaccharide
28. Role of NFkappaB in the mortality of sepsis
29. Increased nuclear factor kappa B activation in critically ill patients who die
30. The pathogenesis of sepsis
31. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome)
32. Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy
33. Pathogenetic mechanisms of septic shock
34. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase
35. Altered immune responses in mice lacking inducible nitric oxide synthase
36. Suppression of interleukin-1β-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-β1 in vascular smooth muscle cells: Evidence for mechanisms other than NF-κB
37. Modulation of cytokine production by transforming growth factor-beta
38. Transforming growth factor beta exerts opposite effects from interleukin-1 beta on cultured rabbit articular chondrocytes through reduction of interleukin-1 receptor expression
39. Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist
40. Deactivation of macrophages by transforming growth factor-β
41. Transforming growth factor-beta 1 inhibits scavenger receptor activity in THP-1 human macrophages
42. Transforming growth factor-β1, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by interleukin-1β in rat smooth muscle cells
43. Arrest of endotoxin-induced hypotension by transforming growth factor β1
44. HMG-1 as a late mediator of endotoxin lethality in mice
45. Role of nitric oxide in vascular permeability after combined burns and smoke inhalation injury
46. Novel roles of nitric oxide in hemorrhagic shock
47. The role of nitric oxide in sepsis: An overview
48. Nitric oxide in septic shock
49. Involvement and dual effects of nitric oxide in septic shock
50. Nitric oxide in sepsis
51. Inhaled nitric oxide and acute lung injury
52. 2 after trauma attenuates pro-inflammatory cytokines and improves survival
53. Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection
54. Cyclooxygenase inhibitors attenuate bradykinin-induced vasoconstriction in septic isolated rat lungs
55. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo
56. Role of cyclooxygenase-2 in oleic acid-induced acute lung injury
57. Mechanisms of the adult respiratory distress syndrome: Selectins
58. Elevated selectin levels after severe trauma: A marker for sepsis and organ failure and a potential target for immunomodulatory therapy
59. Administration of an antibody to E-selectin in patients with septic shock
60. Endothelial-leukocyte adhesion molecules in human disease
61. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation
62. Immunoglobulin E and eosinophil counts are increased after sepsis in trauma patients
63. Cytokine signaling: Regulation of the immune response in normal and critically ill states
64. Association of interleukin-4 plasma levels with traumatic injury and clinical course
65. Interleukin-2-induced lung injury: The role of complement
66. Role of hematopoietic growth factors in non-neutropenic infections and sepsis
67. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappaB to regulate the inducible nitric oxide synthase gene
68. Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells: Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha
69. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B
70. Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium
71. A striking similarity in the organization of the E-selectin and beta interferon gene promoters
72. Cooperativity between two NE-kappa B complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter
73. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cyokine-inducible enhancers
74. Distamycin prolongs E-selectin expression by interacting with a specific NF-kappaB-HMG-I(Y) binding site in the promoter
75. The non-histone chromosomal protein HMG-I(Y) contributes to repression of the immunoblobulin heavy chain germ-line epsilon RNA promoter
76. Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin
77. Independent pathways for derepression of the mouse Ig heavy chain germ-line epsilon promoter: An IL-4 NAF/NF-IL-4 site as a context-dependent negative element
78. Multiple closely-linked NFAT/octomer and HMG-I(Y) binding sites are part of the interleukin-4 promoter
79. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters
80. The role of high-mobility group I(Y) proteins in expression of IL-2 and T cell proliferation
81. Binding of HMG-I(Y) imparts architectural specificity to a positioned nucleosome on the promoter of the human interleukin-2 receptor a gene
82. Nuclear factor of activated T cells contributes to the function of the CD28 response region of the granulocyte macrophage-colony stimulating factor promoter
83. The high mobility group protein HMG-I(Y) can stimulate or inhibit DNA binding of distinct transcription factor ATF-2 isoforms
84. Specific binding of high-mobility-group I (HMGI) protein and histone H1 to the upstream AT-rich region of the murine beta interferon promoter: HMGI protein acts as a potential antirepressor of the promoter
85. The role of HMGI(Y) in the assembly and function of the IFN-beta enhanceosome